RxDoctor Payments Data
★ My doctorsLook up a doctor →

Amit Bar-Or

Neurology · Philadelphia, PANPI 1528508843

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $428,540 of the $595,877 with a category attached, or 71.9%. It is spread thinly across 25 manufacturers, the largest accounting for just 21.6%. Reporting peaked in 2019 at $176,800 and has fallen 59.9% since, to $70,818 in 2025. Among neurology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$595,877in general payments, 2019–2025

Across 347 payments — averaging $1717.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$129K
  • F. Hoffmann-la Roche AG$103K
  • EMD Serono, Inc.$58K
  • Sanofi-aventis U.S. LLC$49K
  • Genentech, Inc.$44K
  • Novartis Pharma AG$41K
  • plus $173K from 19 others
$7,285,007in research payments, 2019–2025

Across 193 payments — averaging $37,746 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$2.8M
  • Novartis Pharma AG$1.9M
  • Genentech, Inc.$1.8M
  • F. Hoffmann-la Roche AG$399K
  • Biogen$263K
  • Sanofi$139K
  • plus $17K from 2 others

What the payments were for

  • Consulting fees$428,54072%
  • Speaking & faculty fees$76,73513%
  • Travel & lodging$82,24214%
  • Food & beverage$6,3331%
  • Education$2,0270%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi60$128,635
F. Hoffmann-la Roche AG64$102,851
EMD Serono, Inc.45$58,390
Sanofi-aventis U.S. LLC12$48,637
Genentech, Inc.45$43,820
Novartis Pharma AG25$40,667
Sanofi US Services Inc.9$32,047
Hoffmann-la Roche Limited9$24,431
GSK16$16,896
Biogen11$15,529
Novartis7$14,128
Bristol Myers Squibb9$13,427
Roche Products Limited10$9,977
Modernatx, Inc.2$6,800
Teva Pharmaceuticals USA, Inc.2$6,080
Merck Serono S.p.a.1$5,895
Shionogi Inc2$5,135
Merck Kgaa1$4,240
Amgen1$4,200
AstraZeneca(2 entities)3$3,450
Merck1$3,390
E.r. Squibb & Sons, L.L.C.1$3,200
Janssen Global Services, LLC1$3,100
Eli Lilly7$847
Genentech USA, Inc.3$106

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$595,877 in reported general payments places this provider in the 95th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania →

Medicare billing

Part B allowed, 2024
$3,045
Medicare patients
21
Services billed
37

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Philadelphia

See the full list for Pennsylvania →

Where these figures come from

Is this you, or does something look wrong? →